What the FDA labels say about taking them together
Alteplase and warfarin
Alteplase's FDA label of January 20, 2026 names warfarin in its warnings and precautions section; the warfarin label PlainMeds reads does not name alteplase. The alteplase label: “… infected site Advanced age Patients currently receiving anticoagulants (e.g., warfarin sodium) Any other condition in which bleeding constitutes a significant hazard or would be particularly difficult to manage because …”
Check it at the source: the alteplase FDA label on DailyMed (effective January 20, 2026, Genentech, Inc.); the warfarin FDA label on DailyMed (effective May 29, 2026, Amneal Pharmaceuticals LLC).
What does the alteplase label say about warfarin?
Alteplase label, warnings and precautions… retinopathy, or other hemorrhagic ophthalmic conditions Septic thrombophlebitis or occluded AV cannula at seriously infected site Advanced age [see Use in Specific Populations (8.5) ] Patients currently receiving anticoagulants (e.g., warfarin sodium) Any other condition in which bleeding constitutes a significant hazard or would be particularly difficult to manage because of its location.
Source: FDA drug label (Activase), Genentech, Inc., effective January 20, 2026 (SPL set c669f77c-fa48-478b-a14b-80b20a0139c2), via openFDA; the full label on DailyMed
What does the warfarin label say about alteplase?
Warfarin's label (effective May 29, 2026) does not name alteplase in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Warfarin Sodium), Amneal Pharmaceuticals LLC, effective May 29, 2026 (SPL set 558b7a0d-5490-4c1b-802e-3ab3f1efe760), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Alteplase | Warfarin | |
|---|---|---|
| Labeled for | Heart attack and coronary artery disease, Blood clots (DVT and PE) | Blood clots (DVT and PE), Atrial fibrillation |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $186.38 per vial 2 mg vial | $0.093 per tablet 2 mg tablet |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once